ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - Episode 2

Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes

February 28, 2025

Pedro C. Barata, MD, MSc, FACP , Moshe Ornstein, MD, Elizabeth Wulff-Burchfield, MD , Kathryn E. Beckermann, MD, PhD

Experts discuss how emerging novel doublet regimens in the frontline setting for advanced renal cell carcinoma may address current unmet needs, highlighting specific biomarkers, patient populations, and clinical scenarios where these combinations could offer distinct advantages over existing standards like immunotherapy (IO)/IO or established IO/tyrosine kinase inhibitor (TKI) combinations.

EP. 1: Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

Now Viewing

EP. 2: Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes

Video content above is prompted by the following:

With novel doublet regimens emerging in the frontline setting for advanced RCC, how do you see these combinations addressing current unmet needs?
Are there specific biomarkers, patient populations, or clinical scenarios where these regimens might offer distinct advantages over existing standards like IO/IO or established IO/TKI combinations?